#Speaker I Terminamos el día con nuestra analista Malgorzata Rogalska en el panel “Due Diligence Decoded: Diving into VC, CVC, and Pharma Practices” Programa completo 👉https://buff.ly/ajutCuH #BioSpain2025 #vc

#Speaker I Seguimos ahora con nuestro Partner Thomas Harth en el panel “Science Meets Capital: De-risking Early Biotech to Unlock Investment” Programa completo 👉https://amconferences.eventsair.com/QuickEventWebsitePortal/biospain-2025/program/Agenda #BioSpain2025 #vc

#Speaker I Hoy, nuestro Partner Guillem Laporta participa en "The Role of Biotechnology in the Pharmaceutical Industry: Present and Future Perspectives" Programa completo 👉https://amconferences.eventsair.com/QuickEventWebsitePortal/biospain-2025/program/Agenda #BioSpain2025 #vc

#Speaker I Hoy, nuestro Managing Partner Joë Jean-Mairet participa en "Guest Nation Switzerland: Entangling the Swiss and Spanish Biotech Ecosystems" Programa completo 👉 amconferences.eventsair.com/QuickEventWe... #BioSpain2025 #vc

#YsiosTeam I 🎉 Excited to announce Laura Argelich's promotion to #Associate at #YsiosCapital! 👏Congrats Laura, well deserved! 🔗Full profile ysioscapital.com/team/laura-a... #vc #talent

#PortfolioNews I Study shows that #MAFTest® developed by our #portfolio company #Ibiomotion may save €105M in early #breast #cancer care. 🔗 Press release - buff.ly/8pAhrip 📄 Full publication here: lnkd.in/d3aUWmpp #Oncology #HealthEconomics #BreastCancer

El fons d'inversió Ysios Capital ha tancat un acord de compravenda amb la multinacional suïssa CSL per un preu màxim de 2.200 milions de dòlars (uns 1.862 milions d&...

🧪 #Barcelona consolida su papel como hub emergente en ciencias de la vida con una operación internacional de gran impacto: Ysios Capital ha anunciado una alianza estratégica entre su participada VarmX y la farmacéutica australiana CSL ✍️ Elena Busquets

📢 #PortfolioNews | Excited to share the strategic deal of our #portfolio company #VarmX with #CSL 💊 🔹Up to $2.2B incl. $117m upfront & milestones 🔹Global Phase 3 of VMX-C001 fully funded 🌍Step closer to market for a major unmet need 👉 buff.ly/aO4iHwV #YsiosPortfolio #vc

#PortfolioNews I MAF Test® now adopted in top #Spanish hospitals to personalize early-stage #breast #cancer treatment. A major step for our #portfolio company #Inbiomotion ! 👉 Full details here - buff.ly/aT4nwud #BreastCancer #Oncology #PortfolioNews #MAFTest

#Press I 🚀¿Qué hay detrás del boom #emprendedor en #Barcelona? Fondos como @ysioscapital.bsky.social lo analizan en este artículo de @thenewbcnpost.bsky.social. No te lo pierdas! 👉 www.thenewbarcelonapost.com/el-tejido-in... #vc #biotech

#PODCAST I 🎙️ Inside Spain’s biggest biotech Series B ever: €119M for SpliceBio 🧬Hear how they built it from scratch, scaled fast & made history. With CEO Miquel Vila-Perelló & @jordixiol.bsky.social (Ysios Capital). 🎧 buff.ly/Cl9x8vL #YsiosPodcast #BiotechPillsWithJordi #vc

#PortfolioNews | Proud to join the $135M Series B of our #portfolio company #SpliceBio, the largest round ever raised by a Spanish biotech 🚀 🧬 Advance SB-007 for #StargardtDisease 🔬Expand #GeneticMedicine pipeline 👉 buff.ly/jey8g9O #VC #Biotech #Innovation #ProteinSplicing

📰 #PRESS I Ysios Capital abre una nueva etapa con #Telescope y mira a la transferencia tecnológica. 🔗 buff.ly/z6H7Zpt More info 👉 buff.ly/btsAIE6 cc/ #Andbank #vc #fund #NasdaqListed

🚀 ¡Enhorabuena a nuestra analista @mrogalska.bsky.social , finalista del Premio Vanguardia de la Ciencia 2025 por su trabajo en el @crg.eu sobre el #espliceosoma humano! 📰 buff.ly/68bKHZS 👏 Orgullosos de contar con su talento en Ysios. #MujeresEnCiencia #YsiosTeam

#Speaker | Don’t miss Karen Wagner at #SwissHLG today at 13:35 ! 🎤 "Managing a portfolio of minority stakes – the view from venture capital" #VC #Biotech #PharmaDeals #LifeSciences

🔬 En 2024, nacieron un 24% menos bebés que hace 10 años. Un cambio demográfico que responde a varios factores, como el aumento de la infertilidad. Para abordar este fenómeno, ReproNovo ha cerrado una ronda de 65 millones de dólares ✍ Ainara Valadez

La biofarmacéutica suiza ReproNovo capta unos 57 millones de euros y abrirá sede en Barcelona

📢 We’re proud to join the $65M Series A of #ReproNovo, advancing Phase 2 therapies in #ReproductiveMedicine & #WomensHealth 🔬Two lead assets: 🔹RPN001 – male infertility 🔹RPN002 – adenomyosis & ART First step into this space for Ysios Capital 👉https://buff.ly/oHEegkT #vc

#Congress | Join us this week at 𝗕𝗶𝗼€q𝘂𝗶𝘁𝘆 𝗘𝘂𝗿𝗼𝗽𝗲 2025 in Bruges! 🙋‍♂️🙋‍♀️Joël Jean-Mairet, Karen Wagner, Thomas Harth, Laura Argelich, Sriram Balusu. 🎯Excited to be back at this leading event for biotech investors. #BioequityEurope #BEE25 #Biotech #VentureCapital

#Speaker I 🎤 Don’t miss Karen Wagner today at #SwissBiotechDay — 12:00 in Room Verseau! "Bridging Borders: Cross-Border Partnering in Biotech" #VC #Biotech #GlobalDeals

💡Com hauria de ser un fons de transferència tecnològica i de creació d’spin-offs biotecnològiques? 🗣️Joël Jean-Mairet, Managing Partner d’@ysioscapital.bsky.social ha compartit el model d’èxit que utilitzen per invertir en projectes científics i acompanyar-los fins a la creació d'empreses

#PortfolioNews | #SparingVision receives #FDA support to launch Phase II trial of SPVN06 in #GeographicAtrophy 🎯 #GA is an advanced form of dry age-related macular degeneration (dAMD) that leads to progressive and irreversible vision loss 👉 buff.ly/m0BlGti #GeneTherapy

#PortfolioNews I Our #portfolio company #Xeltis passes #EIC evaluation for potential €10M funding 🎯Developing regenerative implants to transform vascular surgery through natural tissue regeneration. 👉 buff.ly/rl7BP3W #vc #innovation #dialysis

#PortfolioNews I We’re excited to share that our #portfolio company #Anacond Biomed has enrolled the first U.S. patient in its ATHENA trial. 🎯 Developing next-generation #neurothrombectomy devices for acute ischemic #stroke 👉 buff.ly/vXEDmrK #vc #Spain #Medtech

#PortfolioNewsI We're proud to share that we've joined the oversubscribed $102M financing of our #portfolio company #NeuronaTherapeutics 🎯 Advancing regenerative #celltherapies for drug-resistant #epilepsy and severe #neurological disorders 👉 buff.ly/YHqiseP #vc #CNS

#YsiosTeam I We're thrilled to welcome #SriramBalusu to the @ysioscapital.bsky.social team in #Barcelona! 🎯As an #Analyst he will contribute to the Advisory team for the newly launched 𝙏𝙚𝙡𝙚𝙨𝙘𝙤𝙥𝙚 𝘽𝙞𝙤𝙩𝙚𝙘𝙝 𝙁𝙪𝙣𝙙, managed by Andbank 👉https://bit.ly/SriramB #vc #talent

#Congress | See you today at the #RESIEurope Conference in #Barcelona! 🙋‍♀️🙋‍♀️ Laura Argelich , @mrogalska.bsky.social 🗓️ April 1, 2025 📍Barcelona 👉 buff.ly/dLLcpV9 🎯 Connect with early-stage #investors, #startups, and key players in #lifesciences and #healthcare. #VC #BCN #RESI2025

See you there!!!! 🙋‍♀️ @mrogalska.bsky.social

#PortfolioNews | SpliceBio doses the first patient in the Phase 1/2 ASTRA study of SB-007, the first dual AAV #GeneTherapy for #StargardtDisease! 🎯 Showcasing the power of #ProteinSplicing to tackle diseases caused by #LargeGenes mutations. 👉 buff.ly/HvB3bPR #VC

🚀 See you today at the #International #HealthInvestmentForum by @CataloniaHealth! 🔍 What attracts global investors? How can we make #Catalonia a top destination for health investments? Join the discussion! 🎤 Don’t miss the closing speech by our Managing Partner Joël Jean-Mairet.

#PortfolioNews | Our #quoted company Mineralys Therapeutics (Nasdaq: #MLYS) reports #positive Phase 3 & 2 results for #lorundrostat in #hypertension & announces a $250M #PublicOffering to advance R&D! 👉 buff.ly/qeyUu5K 👉 buff.ly/g18zKmA #ClinicalTrials

#PortfolioNews | NorthSea Therapeutics reports positive results from the Phase 2b ICONA trial of #Icosabutate in #MASH, published in the Journal of Hepatology! 📢 Read more: 👉 buff.ly/49eOq1j 📑 Full publication buff.ly/jZ9cXPW #vc #fibrosis #metabolic

#PortfolioNews I Our portfolio company #Minoryx Therapeutics has dosed the first patient in the Phase 2a TREE study of #leriglitazone for #RettSyndrome! 🧠 🗓️ Results expected in H12026 👉 buff.ly/NycHUxI #CNS #RareDisease #vc

#PortfolioNews | Adcendo receives #FDA clearance for Phase I trial of ADCE-T02 🎯 First-in-class #ADC targeting Tissue Factor in #SolidTumors. 🌍 Now recruiting in #Australia with #US expansion soon! 👉 Read more https://buff.ly/3Dc92qj #Onclogy #vc

#PortfolioNews | Our #portfolio company Neurona Therapeutics plans Phase3 trial in H2 2025 for NRTX-1001, a #celltherapy for drug-resistant #epilepsy. 🔬 Encouraging early data: Up to 97% seizure reduction with no cognitive impairment 📢 Read more: https://buff.ly/3Dh9kfv #VC

#Speaker I Our Managing Partner, Karen Wagner, will join the Early-Stage Investment Panel at #Sachs_ELSF! 📅 Feb 27 | ⏰ 14:05 💡 Insights on #BiotechInvestment, #VC, & #funding strategies for startups. 👉 Details: https://buff.ly/4hSfnGt #EarlyStageFunding #LifeSciencesVC

#PortfolioNews I NorthSea Therapeutics strengthens leadership & advances metabolic, cholestatic & fibrotic disease therapies. 🔬 Key trials ahead! 👉 https://buff.ly/3Quv4HV #vc #MetabolicDiseases

#PortfolioNews I Our #portfolio company ONA Therapeutics strengthens leadership to accelerate first-in-class #ADCs targeting resistant #cancer cells & advancing toward #clinical development. 📢 Read more here https://buff.ly/4gK9vh3 #Oncology #Biotech #Pharma #YsiosPortfolio

📈¿Cómo generar #impacto y #rentabilidad en #ciencia y #tecnología? 💡 Descúbrelo en la mesa redonda "Retos para inversores" con nuestro #Partner Raúl Martín-Ruiz. 📅 20 FEB | ⏰ 13:40h | 📍 Auditorio ABANCA 🔗Programa👉https://buff.ly/4k83b5V #InvertirEnCienciaSíEsRentable

🚀 Join us live for the #BIOSPAIN2025 presentation! 🔬 #Innovation, #investment & #biotech insights, get a first look at what's coming! 💡 Panel with industry voices incl. Guillem Laporta, Partner at Ysios Capital 🔴Live at 10:00 👉 https://buff.ly/4hKlSeC 📅 Full program 👉 https://buff.ly/3QmbfT2

🚀Curious about #Entrepreneurship & #VentureCapital in #LifeSciences? Join Laura Argelich, Analyst at @ysioscapital.bsky.social, at "Bridges to Industry" to learn from top investors! @irbbarcelona.org 📅 Feb 20 |@www.pcb.ub.edu ⏳ Deadline Feb 13! buff.ly/3CBWRTA #BCNHealthInnovationWeek #WomenInVC

#Speaker I Our #Partner Raúl Martín-Ruiz will speak at #BioNeuroscience Congress 🧠 🗓️ Feb 26 ⏰ 12:15 💡 Leading Early-Stage Neuroscience Investors. What CEOs Need To Know 🔥 Don’t miss this top #VC panel on #CNS & #Biotech! 👉 Details: www.broadreach-global.com/bio-neurosci...

#congress I Nos vemos esta semana en el #AcexHealth #InvestorDay organizado por Fundacion PTS ! 🙋‍♂️🧳 Guillem Laporta 👉https://buff.ly/413vACQ 🗓️11 Febrero, 2025 📍Granada #vc #Spain #Innovación #Salud

🎙️Nueva entrega de nuestro #Podcast! PÍLDORAS DE BIOTECH💊 🎯 𝗝.𝗣. 𝗠𝗼𝗿𝗴𝗮𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 📈 Descubre los acuerdos, #tendencias y #retos que marcarán el 2025 en #pharma y #biotech. ▶️ https://buff.ly/3Q5lgnn #YsiosPodcast #BiotechPillsWithJordi

#PortfolioNews I Our #quoted #portfolio company #Mineralys #MLYS completed Enrollment in Explore-CKD Phase 2 Trial of #Lorundrostat for the Treatment of #Hypertension in Subjects with Stage 2 to 3b chronic kidney disease #CKD and #Albuminuria 👉 https://buff.ly/4gqM4t2 #vc #ClinicalTrials

#congress I See you this week at #BioCapitalEurope2025 by EQT Life Sciences! 🙋‍♂️🧳 Guillem Laporta 👉 https://buff.ly/4aI0G5X 📅 5 - 6 February , 2025 📍 Amsterdam

#entrevista I🔬#TelescopeBiotechFund , una apuesta estratégica por la #biotecnología cotizada. Descúbrelo con @jordixiol.bsky.social , Partner en @ysioscapital.bsky.social y Horacio Encabo de Andbank en @capitalradiob.bsky.social ▶️ https://buff.ly/3CkLQG7 #FondosDeInversión #MercadoFinanciero

📢Nos alegra anunciar el lanzamiento de 𝗧𝗲𝗹𝗲𝘀𝗰𝗼𝗽𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗙𝘂𝗻𝗱, gestionado por Andbank , que contará con nuestro asesoramiento especializado. 🎯Fondo con vocación global que invertirá en compañías cotizadas del sector biomédico, principalmente en #Nasdaq y #NYSE 👉 bit.ly/3ZXE8ue #fund

🌍At Ysios Capital, we’re committed to driving positive change in the #LifeSciences investment community! 🎯Proud to support the #ESG Knowledge Project, a groundbreaking initiative shaping #Sustainability standards. buff.ly/4fUWC4i #VentureCapital